GEN Exclusives

More »

GEN News Highlights

Back to Item »

Valeant Takes Unsolicited $5.7B Cash Offer for Cephalon to Shareholders

Cephalon’s recent acquisitions are undermining Valeant’s $73 per share takeover bid, latter’s CEO claims.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?